source
- FDA expands Pluvicto label, allowing most metastatic prostate cancer patients to receive the therapyThe U.S. Food and Drug Administration has approved an expanded label for Novartis’ radiopharmaceutical Pluvicto, permitting its use together with hormone therapy in metastatic prostate cancer. The…
- Supernus and Indivior merge to form CNS-focused company with 11 marketed drugs and $2.2B revenue targetSupernus Pharmaceuticals and Indivior Pharmaceuticals announced an all‑stock merger of equals, creating a central nervous system‑focused company that will combine their product lines and operations…